Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/119284
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuarez, Cristina-
dc.contributor.authorPeña Miralles, Carmen-
dc.contributor.authorArch, Olga-
dc.contributor.authorDomínguez Luzón, Ma. Ángeles (María Ángeles)-
dc.contributor.authorTubau, Fe-
dc.contributor.authorJuan, Carlos-
dc.contributor.authorGavaldá, Laura-
dc.contributor.authorSora, Mercedes-
dc.contributor.authorOliver, Antonio-
dc.contributor.authorPujol Rojo, Miquel-
dc.contributor.authorAriza Cardenal, Javier-
dc.date.accessioned2018-01-25T09:52:49Z-
dc.date.available2018-01-25T09:52:49Z-
dc.date.issued2011-10-13-
dc.identifier.issn1471-2334-
dc.identifier.urihttp://hdl.handle.net/2445/119284-
dc.description.abstractBackground: Studies of recent hospital outbreaks caused by multiresistant P.aeruginosa (MRPA) have often failed to identify a specific environmental reservoir. We describe an outbreak due to a single clone of multiresistant (MR) Pseudomonas aeruginosa (PA) and evaluate the effectiveness of the surveillance procedures and control measures applied. Methods: Patients with MRPA isolates were prospectively identified (January 2006-May 2008). A combined surveillance procedure (environmental survey, and active surveillance program in intensive care units [ICUs]) and an infection control strategy (closure of ICU and urology wards for decontamination, strict compliance with cross-transmission prevention protocols, and a program restricting the use of carbapenems in the ICUs) was designed and implemented. Results: Three hundred and ninety patients were identified. ICU patients were the most numerous group (22%) followed by urology patients (18%). Environmental surveillance found that 3/19 (16%) non-ICU environmental samples and 4/63 (6%) ICU samples were positive for the MRPA clonal strain. In addition, active surveillance found that 19% of patients were fecal carriers of MRPA. Significant changes in the trends of incidence rates were noted after intervention 1 (reinforcement of cleaning procedures): -1.16 cases/1,000 patient-days (95%CI -1.86 to -0.46; p = 0.003) and intervention 2 (extensive decontamination): -1.36 cases/1,000 patient-days (95%CI -1.88 to -0.84; p < 0.001) in urology wards. In addition, restricted use of carbapenems was initiated in ICUs (January 2007), and their administration decreased from 190-170 DDD/1,000 patient-days (October-December 2006) to 40-60 DDD/1,000 patient-days (January-April 2007), with a reduction from 3.1 cases/1,000 patient-days in December 2006 to 2.0 cases/1,000 patient-days in May 2007. The level of initial carbapenem use rose again during 2008, and the incidence of MRPA increased progressively once more. Conclusions: In the setting of sustained MRPA outbreaks, epidemiological findings suggest that patients may be a reservoir for further environmental contamination and cross-transmission. Although our control program was not successful in ending the outbreak, we think that our experience provides useful guidance for future approaches to this problem.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/1471-2334-11-272-
dc.relation.ispartofBmc Infectious Diseases, 2011, vol. 11, p. 272-
dc.relation.urihttps://doi.org/10.1186/1471-2334-11-272-
dc.rightscc-by (c) Suarez, Cristina et al., 2011-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationPseudomonas-
dc.subject.classificationEpidemiologia-
dc.subject.classificationInfeccions nosocomials-
dc.subject.classificationHigiene hospitalària-
dc.subject.otherPseudomonas-
dc.subject.otherEpidemiology-
dc.subject.otherNosocomial infections-
dc.subject.otherHospital hygiene-
dc.titleA large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec607929-
dc.date.updated2018-01-25T09:52:49Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid21995287-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
607929.pdf242.22 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons